⚡️🇺🇸#DOW #отчетность
Dow Chemical Q221 Earnings:
Net Sales: USD13.89B (est USD12.97B)
Operating EPS: USD2.72 (est USD2.45)
Operating EBITDA: USD3.57B (vs. USD757M Y/Y)
Dow Chemical Q221 Earnings:
Net Sales: USD13.89B (est USD12.97B)
Operating EPS: USD2.72 (est USD2.45)
Operating EBITDA: USD3.57B (vs. USD757M Y/Y)
⚡️🇺🇸#ALK #отчетность
Alaska Air - Q2
Non-GAAP EPS of -$0.30 beats by $0.15; GAAP EPS of $3.15 beats by $2.90.
Revenue of $1.53B (+263.4% Y/Y) beats by $10M.
Q2 Load factor of 77.0% vs. a consensus of 76.3%.
RPMs up 524.8%, ASMs up 211.4% and CASM ex down 57.9%.
Generated $840 million in operating cash flow in the second quarter, inclusive of $489 million of PSP funding, bolstered by improved advance bookings on a surge in demand for air travel.
Alaska Air - Q2
Non-GAAP EPS of -$0.30 beats by $0.15; GAAP EPS of $3.15 beats by $2.90.
Revenue of $1.53B (+263.4% Y/Y) beats by $10M.
Q2 Load factor of 77.0% vs. a consensus of 76.3%.
RPMs up 524.8%, ASMs up 211.4% and CASM ex down 57.9%.
Generated $840 million in operating cash flow in the second quarter, inclusive of $489 million of PSP funding, bolstered by improved advance bookings on a surge in demand for air travel.
⚠️☢️🇰🇷#крипто #юкорея #регулирование #биржи
южнокорейский регулятор предупреждает: у криптобирж осталось 2 мес, чтобы зарегистрироваться
Крайний срок - 24 сентября
южнокорейский регулятор предупреждает: у криптобирж осталось 2 мес, чтобы зарегистрироваться
Крайний срок - 24 сентября
⚡️🇺🇸#T #отчетность
AT&T Q221 Earnings:
Revenue: USD44B (est USD42.76B)
Free Cash Flow: USD7B (est USD6.15B)
Raises Year Revenue Growth View Sees: 2-3%
Boosts Year-End HBO MAX Forecast To 70-73M Subscribers
Adj EPS: USD0.89 (est USD0.80)
AT&T Q221 Earnings:
Revenue: USD44B (est USD42.76B)
Free Cash Flow: USD7B (est USD6.15B)
Raises Year Revenue Growth View Sees: 2-3%
Boosts Year-End HBO MAX Forecast To 70-73M Subscribers
Adj EPS: USD0.89 (est USD0.80)
⚡️🇺🇸#LUV #отчетность
Southwest Airlines Q221 Earnings:
Operating Revenue: USD4.01B (est USD3.93B)
Passenger Revenue: USD3.57B (est USD3.56B)
Load Factor: 82.9% (est 80%)
Hopeful To Be Profitable In Q3, Q4
Adj EPS: USD-0.35 (est USD-0.26)
Southwest Airlines Q221 Earnings:
Operating Revenue: USD4.01B (est USD3.93B)
Passenger Revenue: USD3.57B (est USD3.56B)
Load Factor: 82.9% (est 80%)
Hopeful To Be Profitable In Q3, Q4
Adj EPS: USD-0.35 (est USD-0.26)
⚡️💥🇺🇸#MRK
FDA Approves KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Combination for Patients With Certain Types of Advanced Endometrial Carcinoma
FDA Approves KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Combination for Patients With Certain Types of Advanced Endometrial Carcinoma
⚡️🇺🇸#BX #отчетность
Blackstone Q221 Earnings:
AUM: USD684.0B (est USD665.88B)
Total Segment Revenue: USD2.12B (est USD1.88B)
Fee Related Earnings: USD704.1M (est USD664.4M)
Distributable Income/Share: USD82C (est USD79C)
Blackstone Q221 Earnings:
AUM: USD684.0B (est USD665.88B)
Total Segment Revenue: USD2.12B (est USD1.88B)
Fee Related Earnings: USD704.1M (est USD664.4M)
Distributable Income/Share: USD82C (est USD79C)
⚡️🇺🇸#AAL #отчетность
American Airlines Group Q221 Earnings:
Operating Revenue: USD7.48B (est USD7.48B)
Passenger Revenue: USD6.55B (est USD6.53B)
Load Factor: 77.0%
Adj Loss/Share: USD1.69 (est Loss/Share: USD1.72)
Sees Q3 Capacity: -15% To -20% From 2019
American Airlines Group Q221 Earnings:
Operating Revenue: USD7.48B (est USD7.48B)
Passenger Revenue: USD6.55B (est USD6.53B)
Load Factor: 77.0%
Adj Loss/Share: USD1.69 (est Loss/Share: USD1.72)
Sees Q3 Capacity: -15% To -20% From 2019
⚡️🇺🇸#NEM #отчетность
Newmont Q2
Non-GAAP EPS of $0.83 beats by $0.07; GAAP EPS of $0.80 beats by $0.06.
Revenue of $3.06B (+29.1% Y/Y) misses by $50M.
Newmont Q2
Non-GAAP EPS of $0.83 beats by $0.07; GAAP EPS of $0.80 beats by $0.06.
Revenue of $3.06B (+29.1% Y/Y) misses by $50M.
⚡️🇺🇸#BIIB #отчетность
Biogen Q221 Earnings:
Revenue: USD2.78B (est USD2.62B)
Adj EPS: USD5.68 (est USD4.52)
Sees FY Revenue: USD10.65B To USD10.85B (saw: USD10.45B To USD10.75B)
Still Sees FY Adj EPS: USD17.50 To USD19.00 (est USD18.40)
Go FDA Breakthrough Therapy Designation For Lecanemab
Biogen Q221 Earnings:
Revenue: USD2.78B (est USD2.62B)
Adj EPS: USD5.68 (est USD4.52)
Sees FY Revenue: USD10.65B To USD10.85B (saw: USD10.45B To USD10.75B)
Still Sees FY Adj EPS: USD17.50 To USD19.00 (est USD18.40)
Go FDA Breakthrough Therapy Designation For Lecanemab